Medtronic looks to be back on track with its renal denervation plans, after announcing its Symplicity Spyral system got off to a good start with positive six-month results in the SPYRAL HTN-ON MED pilot study. The data, presented at EuroPCR 2018 in Paris, showed that Symplicity Spyral was able to reduce blood pressure significantly in hypertensive patients prescribed anti-hypertension medications, with no major adverse safety events out to six months.
Positive six-month results, the first-ever data from Medtronic PLC's SPYRAL HTN-ON MED pilot study of its Symplicity Spyral renal denervation (RDN) system, hold the promise of setting the medtech giant back on track and toward a market opportunity worth billions of dollars.
The study results, announced May 23 at EuroPCR in Paris, showed that Symplicity Spyral reduced blood pressure significantly in hypertensive...